Citigroup Inc Vertex Pharmaceuticals Inc Put Options Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 12, 2024	SELL	$392.81 - $485.53 $12.8 Million - $15.8 Million	-32,600 Reduced 51.99%	30,100 $14.1 Million
Q1 2024 May 10, 2024	SELL	$407.69 - $446.08 $11.3 Million - $12.4 Million	-27,800 Reduced 30.72%	62,700 $26.2 Million
Q4 2023 Feb 09, 2024	BUY	$343.0 - $410.68 $12.1 Million - $14.5 Million	35,300 Added 63.95%	90,500 $36.8 Million
Q3 2023 Nov 09, 2023	BUY	$338.18 - $362.46 $11.7 Million - $12.6 Million	34,700 Added 169.27%	55,200 $19.2 Million
Q2 2023 Aug 10, 2023	BUY	$314.42 - $351.91 $6.45 Million - $7.21 Million	20,500 New	20,500 $7.21 Million
Q4 2022 Feb 09, 2023	SELL	$285.76 - $321.48 $4.29 Million - $4.82 Million	-15,000 Reduced 55.56%	12,000 $3.47 Million
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $2.79 Million - $3.12 Million	10,200 Added 60.71%	27,000 $7.82 Million
Q2 2022 Aug 10, 2022	SELL	$234.96 - $292.55 $27.8 Million - $34.6 Million	-118,400 Reduced 87.57%	16,800 $4.73 Million
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $28.4 Million - $33.5 Million	128,200 Added 1831.43%	135,200 $35.3 Million
Q3 2021 Nov 10, 2021	BUY	$181.39 - $202.99 $1.27 Million - $1.42 Million	7,000 New	7,000 $1.27 Million

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.